For Immediate Release
Media Contact: Bob Cooper
Date: August 30, 2012
Johnson and Johnson Subsidiary to Pay States $181 Million in Drug Marketing Settlement
(Boise) – Idaho has joined with 37 other states in a $181 million settlement with Janssen Pharmaceuticals, Inc., Attorney General Lawrence Wasden said today. The agreement resolves the states' claims that Janssen, a subsidiary of Johnson and Johnson, improperly marketed the antipsychotic drugs Risperdal, Risperdal Consta, Risperdal M-Tab and Invega.
The states alleged that Janssen engaged in unfair and deceptive practices when it marketed Risperdal for off-label uses, targeting patients with Alzheimer’s disease, dementia, depression, and anxiety. These uses were not FDA-approved and Janssen had not established that Risperdal was safe and effective for these uses. Risperdal is among a class of drugs known as atypical or second generation antipsychotics. Federal law prohibits pharmaceutical manufacturers from promoting their products for off-label uses, although physicians may prescribe drugs for those uses.
Under terms of the settlement, Janssen agreed to change how it promotes and markets its atypical antipsychotics and to refrain from any false, misleading, or deceptive promotion of the drugs. The settlement also restricts Janssen from promoting its atypical antipsychotic drugs for “off-label” uses that the U.S. Food and Drug Administration (“FDA”) has not approved.
Additionally, for a five-year period, Janssen:
Idaho will receive $2,847,890 as its share of the settlement. The money will be deposited into the Consumer Protection Account, which partially funds the Attorney General’s consumer protection operations.
In agreeing to the settlement, Janssen Pharmaceuticals admitted no wrongdoing.
- End -